Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between grip strength and the diabetes complications severity index (DCSI) in patients with type 2 diabetes mellitus.

Diabetes & metabolic syndrome·2026
Same author

Indicators for predicting continuous insulin infusion therapy-related hypokalemia: multicenter retrospective cohort study.

Endocrine journal·2026
Same author

Clinical impact of a rapid-acting insulin bolus at the initiation of continuous insulin infusion therapy in patients with hyperglycemic crisis: a propensity score-matched analysis.

Diabetology international·2026
Same author

Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.

Scientific reports·2026
Same author

Persistence of fixed-dose combinations including dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes in Japan: analysis using a claims database.

Expert opinion on pharmacotherapy·2026
Same author

Insulinoma complicated with hypergastrinemia in a subject with type 2 diabetes mellitus: a case report.

Diabetology international·2026

Related Experiment Videos

[Alogliptin].

Akihito Tanabe1, Kohei Kaku

  • 1Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kawasaki Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 21, 2011
PubMed
Summary
This summary is machine-generated.

Alogliptin, a selective dipeptidyl peptidase-4 inhibitor, effectively lowers HbA1c in type 2 diabetes patients. It showed benefits in monotherapy and as an add-on treatment without significant side effects or weight changes.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Alogliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor for type 2 diabetes.
  • It exhibits high selectivity due to its unique chemical structure.
  • Launched initially in Japan, its global profile is under review.

Purpose of the Study:

  • To review the pharmacological and clinical profiles of Alogliptin.
  • To present preclinical and clinical evidence on Alogliptin's efficacy and safety.

Main Methods:

  • Review of preclinical and clinical studies on Alogliptin.
  • Analysis of data from monotherapy and add-on therapy studies.

Main Results:

  • Alogliptin monotherapy (12.5-25 mg daily) reduced HbA1c by 0.4-0.8% and increased active glucagon-like peptide-1 (GLP-1).
  • No significant body weight changes or adverse events were observed.
  • Add-on therapy with pioglitazone or voglibose resulted in an additional 0.9% HbA1c decrease over 12 weeks.

Conclusions:

  • Alogliptin demonstrates effective glycemic control in type 2 diabetes.
  • Its high selectivity and favorable safety profile support its use.
  • Clinical evidence supports Alogliptin's role in managing type 2 diabetes, both as monotherapy and in combination regimens.